GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment

GO Therapeutics, Inc. (GO) announced on 10/2/18 that it has entered into a license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche). Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.